

15th International Congress of TDM & Clinical Toxicology

Kyoto, Japan

Immunosuppressive Drugs Scientific Committee Meeting

Tuesday 26, September 2017, 9:15-10:30

Minutes

Attending members:

Teun van Gelder, Loralie Langman, Uwe Christians, Maria Shipkova, Eberhard Wieland, Tomasz Pawinski, Pawel Kunicki, Olga Millán, Florian Lemaitre, Binu S. Mathew, Stein Bergan, Mercè Brunet

1. Mercè Brunet on behalf of Dennis Hesselink and herself opens the meeting and welcomes all attending members of the Scientific Committee. As new members Florian Lemaitre and Binu S. Mathew were welcomed.
2. Mercè Brunet on behalf of Dennis Hesselink gave a brief summary of the activities 2016-2017. This information is available on the website.
3. Dennis A. Hesselink will step down as Chair after this meeting; Mercè Brunet will be his successor. Stein Bergan will be the new Vice-Chair. As he was the only candidate to apply for this position, no voting was necessary.

4. Suggested projects 2018-2019

4.1. Consensus Documents

Mercè Brunet and Stein Bergan will coordinate the **Second Consensus Document on TDM and personalized treatment for Tacrolimus**. The goals of this consensus document are detailed in annex1. We discussed during the meeting the topics that should be included in this document. Each topic will be prepared by specific groups conducted by one or two leaders. The general coordinators will carry out the entire project, working with the leaders. This way the development of the manuscript will go more smoothly and we will be able to meet the established deadlines. The Second Consensus Document on tacrolimus will be prepared during 2018 and published in TDM at the end of 2018.

For those members who were not able to attend the meeting in Kyoto, please let me know if you are interested in participating. If so, I will contact you personally.

Second Consensus Document on Biomarkers in Transplantation. Uwe Christians, as Leader of the Biomarker Working Group, will coordinate this consensus document. The preparation of the manuscript will take place during 2018, to be published in TDM, 2019. Uwe Christians will contact all members of the BWG.

4.2. Participation in Symposiums and workshops

All members attending participate in the contributions to the scientific program of **16th IATDMCT Congress, Brisbane 2018**. Proposals for plenary lectures and symposiums: Plenary: Drug monitoring of tacrolimus why does it not work? U Christians; Symposium: Quo Vadis Pharmacodynamic monitoring of ISDs?; Symposiums TDM of mTOR inhibitors in non transplant setting: to do or not to do? Teun van Gelder

Mercè Brunet proposed our participation on a Symposium on precise medicine in the XXXIV Congress SECQ&FLM (EuroMedLab) Joint Scientific Meeting. Insight PK-PG-PD monitoring combination and its clinical impact in personalized immunosuppression. With the participation of some members of the Scientific Committee of Immunosuppressive Drugs of the IATDMCT. Barcelona 2019 (Coordination M Brunet)

4.3. Active participation in the Compass was considered.

Members present discuss whether one or two articles could be published per year. Some proposals on manuscripts were made: The implementation of Treg monitoring as a guide to personalized immunosuppression in clinical transplantation. E Wieland & M Shipkova; miRNAs: Insights its usefulness to predict the risk of rejection and graft clinical outcome. O Millán & M Brunet; Tacrolimus Pop PK/PG model in kidney and liver transplantation. L Elens & S Bergan.

4.4. New activities of the Working Groups of the Immunosuppressive Drugs Committee

Biomarkers Working Group. Leader: Uwe Christians

Uwe Christians addressed all the attending members at the end of the meeting concerning the new activities underway. He will contact all members of the BWG in order to coordinate the second Consensus Document on Biomarkers and other activities of this WG during 2018-2019.

Standardization of ISD TDM Working Group. Leaders: Christoph Seeger, Loralie Langman

Loralie Langman had to leave our committee meeting early, and she doesn't get a chance to talk with detail about the new standardization project of immunosuppressive drug monitoring. A few days ago Loralie contacted all members of the Scientific Committee about the new project that essentially has 2 parts: The analytical standardisation driven by the IFCC and a committee co-chaired by Loralie and Christoph Seger, and the implementation of the standardisation leading to all laboratories providing "identical" results, which will be driven by the ISDs Committee. It is expected that a great deal of our members will participate.

Intracellular tacrolimus measurement Working Group. Leader: Florian Lemaitre.

This new Working Group was presented during the meeting in Kyoto. The first move will be to write practice guidelines about the analytical and pre-analytical aspects of monitoring intracellular levels of ISDs (to be published in TDM). Those who are interested in participating, please contact Florian: florian.lemaitre@chu-rennes.fr

At the end of the meeting Mercè Brunet, as the new Chair, thanks Dennis Hesselink for his contributions to this Committee.

MB - Sept 26, 2017.